RWD Differences Across 6 European HTAs

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR)’s Value in Health recently published a new study revealing notable differences in how European health technology assessment (HTA) agencies assess real-world data. Find out more here. (Source: ISPOR)

You might also be interested in:

HTA in Europe: Key Success Factors for Positive HTA Recommendations June 21, 2018
Q&A With Lou Garrison on RWE, HTA April 21, 2018
Report: RWE has Limited Use in Managed Care Formulary Decisions April 7, 2018
Bringing RWE, RWD to Center Stage January 17, 2018
NPC: RWD, RWD Continue to Grow May 30, 2018
ISPOR Special Task Force Report Focuses on Range of Issues February 26, 2018
How Will the FDA’s Payer Communications Guidance Affect… July 18, 2018